NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its 2018 Q1 net loss shrank 19 percent year over year, as it moves forward with studies intended to support a final clinical validation by the end of the year.

The liquid biopsy firm's net loss for the three months ended March 31, 2018 was $3.8 million, or $.12 per share, compared to a net loss of $4.7 million, or $.16 per share, in the same quarter last year. It matched the consensus Wall Street estimate of a loss of $.12 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.